Cargando…

Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors

Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lijun, Li, Yang, Jiang, Ning, Song, Xue, Xu, Jianhua, Zhu, Xiangzhi, Chen, Cheng, Kong, Cheng, Wang, Xiaohua, Zong, Dan, Li, Luan, Han, Cen, Yin, Li, He, Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986630/ https://www.ncbi.nlm.nih.gov/pubmed/35250004 http://dx.doi.org/10.1097/CJI.0000000000000415

Ejemplares similares

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

892. Risk Factors for Adverse Events in Children Receiving Outpatient Antibiotic Therapy
por: Gillon, Jessica, et al.
Publicado: (2019)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
por: Wu, Chiao-En, et al.
Publicado: (2020)

Effect of exposure to antibiotics on the gut microbiome and biochemical indexes of pregnant women
por: Su, Yao, et al.
Publicado: (2021)

Fluoroquinolone antibiotics and adverse events
por: Baggio, Diva, et al.
Publicado: (2021)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Association between PD‐1 inhibitor‐related adverse events and frailty assessed by frailty index in lung cancer patients
por: Li, Jun, et al.
Publicado: (2023)

Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models
por: Kim, Woorim, et al.
Publicado: (2021)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy
por: Dai, Lili, et al.
Publicado: (2020)

Adverse events in women and children who have received intrapartum antibiotic prophylaxis treatment: a systematic review
por: Seedat, Farah, et al.
Publicado: (2017)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
por: Huang, Guili, et al.
Publicado: (2022)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Three‐Component Mixture Model‐Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System
por: Zhang, Pengyue, et al.
Publicado: (2018)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
por: Zhang, You-Cheng, et al.
Publicado: (2023)

Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses
por: Li, Jing, et al.
Publicado: (2019)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome
por: Wang, Le, et al.
Publicado: (2020)

Low Prognostic Nutritional Index Contributes to High Adverse Events in Preeclampsia
por: Wei, Songquan, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis
por: Li, Shuluan, et al.
Publicado: (2021)

Critical values of monitoring indexes for perioperative major adverse cardiac events in elderly patients with biliary diseases
por: Zhang, Zong-Ming, et al.
Publicado: (2022)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
por: Mouri, Atsuto, et al.
Publicado: (2021)

Adverse Events Releated to Antibiotic Use in Patients with Myasthenia Gravis
por: Zeitler, Kristen, et al.
Publicado: (2017)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose
por: Chen, Liling, et al.
Publicado: (2023)

Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy
por: Fang, Qiyu, et al.
Publicado: (2022)

Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2021)

Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
por: Kang, Xindan, et al.
Publicado: (2023)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
por: Chen, Jinghan Jenny, et al.
Publicado: (2015)

Left atrial area index predicts adverse cardiovascular events in patients with unstable angina pectoris
por: Li, Yi-Fan, et al.
Publicado: (2016)

Major Adverse Cardiovascular Events after Treatment in Early-stage Breast Cancer Patients Receiving Hormone Therapy
por: Chou, Ying-Hsiang, et al.
Publicado: (2020)

Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials
por: Yang, Wenwei, et al.
Publicado: (2019)

Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis
por: Sun, Xiaoying, et al.
Publicado: (2017)

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma
por: Zhao, Jing-Jing, et al.
Publicado: (2020)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nv37tfip5uoq8b4u1n03jadt5s